Inflammatory Bowel Disease


Inflammatory bowel diseases (IBD) are chronic, inflammatory conditions of the gastrointestinal tract and consist of Crohn’s disease (CD) and ulcerative colitis (UC). IBD has the highest incidence in teenagers and young adult, and diarrhea and abdominal pain significantly impacts on quality of life. The cause of these diseases is uncertain and therefore there is no cure for either CD or UC. IBD is thought to arise from an aberrant immune response in genetically susceptible individuals. Current therapies attempt to improve symptoms by modulating the immune system but research now focuses on what might be driving this immune response and the most likely candidate is the gut microbiome. Preclinical studies, in collaboration with scientists in France (Langella P, INRA Paris), are elucidating the roles and therapeutic potential of commensal bacteria in models of IBD. A 2015 study by Natividad J et al found that selected bacterial groups, involved in gut health, are important for protecting the colon against injury and inflammation in mouse models colonized with gut bacteria from UC patients and healthy controls. A recent study from the Farncombe Family Digestive Health Research Institute (Moayyedi P et al. Gastroenterology 2015) assessed how modulating gut bacteria with fecal microbiota therapy (FMT) can induce remission in patients with active UC in the first randomized trial in this area. It is an example of the Institute’s ability to translate promising results of preclinical studies into patients. Psychiatric co-morbidity is common in chronic GI diseases including IBD an reflects the intimate relationship between the gut and brain. Previous preclinical studies in the Institute has shown that gut inflammation alters brain function and behaviour (Bercik P Gastroenterology 2010) and can be attenuated with selected probiotics (Bercik P 2011). More recently that group has shown that in a preclinical model of early stress that results in persistent changes in behaviour, the expression of depression was dependent on the presence of gut bacteria (De Palma G et al Nat Commun 2015).

Related Papers

  • Ecobiotherapy Rich in Firmicutes Decreases Susceptibility to Colitis in a Humanized Gnotobiotic Mouse Model. -
    Natividad Jane M, Pinto-Sanchez Maria I, Galipeau Heather J et al.
    Inflamm Bowel Dis. Link: 26060932
  • Impaired parasympathetic function increases susceptibility to inflammatory bowel disease in a mouse model of depression. -
    Ghia Jean-Eric, Blennerhassett Patricia, Collins Stephen M et al.
    J Clin Invest. Link: 18451995
  • The vagus nerve: a tonic inhibitory influence associated with inflammatory bowel disease in a murine model. -
    Ghia Jean Eric, Blennerhassett Patricia, Kumar-Ondiveeran Harry et al.
    Gastroenterology. Link: 17030182
  • Faecalibacterium prausnitzii prevents physiological damages in a chronic low-grade inflammation murine model. -
    Martín Rebeca, Miquel Sylvie, Chain Florian et al.
    BMC Microbiol. Link: 25888448
  • Modulation of intestinal barrier by intestinal microbiota: pathological and therapeutic implications. -
    Natividad Jane M M, Verdu Elena F, et al.
    Pharmacol Res. Link: 23089410
  • Commensal and probiotic bacteria influence intestinal barrier function and susceptibility to colitis in Nod1-/-; Nod2-/- mice. -
    Natividad Jane M M, Petit Valerie, Huang Xianxi et al.
    Inflamm Bowel Dis. Link: 22162005
  • Investigating intestinal inflammation in DSS-induced model of IBD. -
    Kim Janice J, Shajib Md Sharif, Manocha Marcus M et al.
    J Vis Exp. Link: 22331082

  • People working in this area

    Share on FacebookTweet about this on TwitterShare on Google+Share on LinkedIn